Spyre Therapeutics' SPY001 demonstrates a >90-day half-life in Phase 1 trials, suggesting potential for quarterly or bi-annual subcutaneous maintenance dosing in IBD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.